Texture analysis of non-contrast-enhanced computed tomography for assessing angiogenesis and survival of soft tissue sarcoma

Journal of Computer Assisted Tomography

Volumn 39, Issue 4, 2015, Pages 607-612

  Hayano, Koichi ^a   Tian, Fang ^a,b   Kambadakone, Avinash R ^a   Yoon, Sam S ^c   Duda, Dan G ^a   Ganeshan, Balaji ^d   Sahani, Dushyant V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Computed tomography; Heterogeneity; Soft tissue sarcoma; Texture analysis

Indexed keywords

BLOOD VESSELS; COMPUTERIZED TOMOGRAPHY; ENDOTHELIAL CELLS; FACTOR ANALYSIS; TUMORS;

ANGIOGENESIS; COMPUTED TOMOGRAPHIC; COMPUTED TOMOGRAPHY; HETEROGENEITY; OVERALL SURVIVAL; POSITIVE CORRELATIONS; SOFT TISSUE SARCOMA; TEXTURE ANALYSIS; TEXTURE PARAMETERS; TUMOR ANGIOGENESIS;

ENTROPY;

BEVACIZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAPILLARY DENSITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ENTROPY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE QUALITY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOLOGICAL PARAMETERS; SOFT TISSUE SARCOMA; TREATMENT DURATION; ADJUVANT THERAPY; BLOOD; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOVASCULARIZATION (PATHOLOGY); OBSERVER VARIATION; PHASE 2 CLINICAL TRIAL; RADIOGRAPHY; SARCOMA; SURVIVAL;

ADULT; AGED; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OBSERVER VARIATION; SARCOMA; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84964693952     PISSN: 03638715     EISSN: 15323145     Source Type: Journal    
DOI: 10.1097/RCT.0000000000000239     Document Type: Article

References (35)

1. Goh V, Ganeshan B, Nathan P, et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011;261:165-171.
2. Pries AR, Cornelissen AJ, Sloot AA, et al. Structural adaptation and heterogeneity of normal and tumor microvascular networks. Plos Comput Biol. 2009;5:e1000394.
3. Ganeshan B, Panayiotou E, Burnand K, et al. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: A potential marker of survival. Eur Radiol. 2012;22:796-802.
4. Ganeshan B, Skogen K, Pressney I, et al. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol. 2012;67:157-164.
5. Ng F, Ganeshan B, Kozarski R, et al. Assessment of primary colorectal cancer heterogeneity by using whole-Tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology. 2013;266:177-184.
6. Hayano K, Yoshida H, Zhu AX, et al. Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib. Dig Dis Sci. 2014;59:1996-2003.
7. Ganeshan B, Goh V, Mandeville HC, et al. Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology. 2013; 266:326-336.
8. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19:3203-3209.
9. Yoon SS, Chen YL, Kirsch DG, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol. 2010;17:1515-1529.
10. Pawlik TM, Pisters PW, Mikula L, et al. Long-Term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13:508-517.
11. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197-203.
12. Yoon SS, Duda DG, Karl DL, et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2011;81:1081-1090.
13. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020-1033.
14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
15. Davnall F, Yip CS, Ljungqvist G, et al. Assessment of tumor heterogeneity: An emerging imaging tool for clinical practice Insights Imaging. 2012;3: 573-589.
16. Miles KA, Ganeshan B, Griffiths MR, et al. Colorectal cancer: Texture analysis of portal phase hepatic CTimages as a potential marker of survival. Radiology. 2009;250:444-452.
17. Miles KA, Ganeshan B, Hayball MP. CT texture analysis using the filtration-histogram method: What do the measurements mean Cancer Imaging. 2013;13:400-406.
18. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914-1926.
19. Singer S, Corson JM, Gonin R, et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg. 1994;219:165-173.
20. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21:2719-2725.
21. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791-796.
22. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1, 041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679-1689.
23. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma.A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996; 14:869-877.
24. Ueda T, Yoshikawa H, Mori S, et al. Influence of local recurrence on the prognosis of soft-Tissue sarcomas. J Bone Joint Surg Br. 1997;79: 553-557.
25. Durrett R, Foo J, Leder K, et al. Intratumor heterogeneity in evolutionary models of tumor progression. Genetics. 2011;188:461-477.
26. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6: 327-338.
27. Duda DG, Willett CG, Ancukiewicz M, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15: 577-583.
28. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393-410.
29. Comandone A, Foglione A, Berardengo E, et al. Neoangiogenesis in adult soft tissue sarcomas (STS): prognostic significance of microvessel density (MVD) correlated to grading and stage. A perspective study. J Bone Joint Surg Br Proc. 2009;91:269-269.
30. Kubo T, Shimose S, Fujimori J, et al. Diversity of angiogenesis among malignant bone tumors. Molec Clin Oncol. 2013;1:131-136.
31. Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology. 2008;246:935-940.
32. Kamiya A, Murayama S, Kamiya H, et al. Kurtosis and skewness assessments of solid lung nodule density histograms: differentiating malignant from benign nodules on CT. Jpn J Radiol. 2014;32:14-21.
33. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-337.
34. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6: 392-401.
35. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674.